Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
CANDOR-update: aanhoudend PFS-voordeel carfilzomib, dexamethason en daratumumab bij RRMM
feb 2022 | MM